Enovis (ENOV) Q4 2025 earnings review
Growth Hits the Brakes as Impairments Erase Profits
Enovis stumbled into the end of FY25. Despite management touting 'commercial momentum,' organic growth decelerated sharply to 2% in Q4—a dramatic slowdown from 7% in Q3. The bottom line was crushed by a $501 million goodwill impairment charge, bringing total FY25 write-downs to a staggering $1.05 billion. Furthermore, Adjusted EBITDA margins contracted year-over-year in the fourth quarter. While management's FY26 guidance projects a stable re-acceleration back to 4-6% organic growth, the immediate reality is a quarter marked by slowing sales, compressing profitability, and questions regarding the true carrying value of past acquisitions.
🐂 Bull Case
While U.S. markets slowed, International Reconstructive sales remained a bright spot, growing 5.1% organically in Q4 and 10.2% for the full year, indicating the Lima cross-selling thesis continues to bear fruit.
Management expects FY26 organic revenue growth of 4-6% and EBITDA margin expansion, implying they view Q4's sharp deceleration as a temporary blip rather than a structural ceiling.
🐻 Bear Case
Total organic growth collapsed from 7% in Q3 to 2% in Q4. The Reconstructive segment, previously the company's growth engine, dropped to just 3.3% organic growth, while the Prevention & Recovery segment flatlined at 0.5%.
A $1.05 billion non-cash goodwill impairment in FY25 (following a $645M charge in FY24) signals a sustained disconnect between the company's market capitalization and the price it paid for past acquisitions.
⚖️ Verdict: 🔴
Bearish. The aggressive narrative of 'above-market organic growth' contradicts the Q4 data. A 2% organic growth rate, coupled with YoY margin contraction and massive asset write-downs, creates significant 'show-me' risk for FY26.
Key Themes
The Growth Engine Stalls
Reconstructive organic growth is decelerating rapidly. After posting 13% comp growth in Q1 and 9% in Q3, the segment slowed to just 3.3% organically in Q4. U.S. Reconstructive grew only 1.5% on a reported basis. Given that Recon is Enovis's primary margin and growth driver, this sudden deceleration raises questions about the cadence of new product innovations (like Nebula and ARG) and intensifying competitive pressures.
Goodwill Impairments Become a Habit
For the second consecutive year, Enovis took a massive Q4 goodwill impairment charge—$501 million this quarter, bringing the FY25 total to $1.05 billion. Management evaluates this against their shrinking market capitalization relative to carrying values. While non-cash, writing down over $1.6 billion in assets across 24-25 heavily undermines the perceived value and integration success of past M&A (including Lima).
EBITDA Margins Reversing
Adjusted EBITDA margin for Q4 came in at 19.4%, a deceleration from the 20.1% achieved in Q4 2024. Consequently, Adjusted EPS also reversed, falling to $0.95 from $0.98 a year ago. This suggests that previously cited productivity initiatives (EGX system) are struggling to offset operating expenses, R&D investments, or lingering tariff headwinds in a slower-growth environment.
Operational Discipline & Debt Focus
Despite top-line softness, management emphasized achieving positive free cash flow and executing on debt reduction in FY25. With full-year Adjusted Gross Margins improving to 61.0% from 59.3%, the underlying manufacturing mix is healthy. The focus for FY26 remains strictly on financial discipline and capital-efficient growth rather than dilutive acquisitions.
Prevention & Recovery Flatlining
The P&R segment is stable but stagnant. Organic growth decelerated to essentially zero (0.5%) in Q4. U.S. Bracing & Support specifically reported a 0.7% decline in sales. Even factoring in the Q4 divestiture of the Dr. Comfort business, the core legacy business is failing to provide meaningful top-line support to offset Recon's slowdown.
Navigating a Dynamic Macro Environment
Management explicitly cited operating in a 'dynamic global environment' and remaining 'attentive to the evolving macro environment' going into 2026. This language typically pre-empts ongoing headwinds from inflation, supply chain nuances, and previously disclosed tariff pressures that materially impacted the P&L throughout FY25.
Other KPIs
Accelerating. Up from 60.1% in 24Q4. This highlights that manufacturing productivity (EGX) and product mix are functioning well at the gross level; the profitability leaks are happening further down the income statement in SG&A and operating expenses.
Decelerating violently. Due to the massive impairment charges, total goodwill on the balance sheet has collapsed from $1.69 billion at the end of FY24 down to $718 million. Intangible assets also decreased to $1.24 billion.
Guidance
Accelerating vs current trajectory. The midpoint implies roughly 4.1% reported growth over FY25's $2.248B, with organic growth guided at 4-6%. This assumes the severe Q4 deceleration (2% organic) was temporary and growth normalizes upward.
Accelerating. Implies approximately 6.7% YoY growth at the midpoint ($430M) compared to $403M in FY25. Because EBITDA growth is guided higher than revenue growth, this bakes in a resumption of margin expansion in FY26.
Accelerating. The midpoint of $3.625 implies roughly 9.8% YoY growth over FY25's $3.30, reflecting operating leverage and lower expected interest expenses from continued debt paydown.
Key Questions
Bridging the Q4 Slowdown
Organic growth fell sharply to 2% in Q4, yet your 2026 guidance assumes a re-acceleration to 4-6%. What specific market dynamics or product launches give you the confidence that Q4 was just a blip?
Goodwill and Asset Values
With another $500M+ impairment this quarter, bringing the total to over $1 billion for the year, are we finally at a clearing point for the carrying value of the Recon and P&R units, or is there further write-down risk if the macro environment worsens?
EBITDA Margin Disconnect
Adjusted Gross Margins expanded over 100 bps in Q4, yet Adjusted EBITDA margins compressed by 70 bps. Can you unpack the specific operating expense investments or tariff headwinds that drove this negative leverage?
U.S. Reconstructive Weakness
U.S. Reconstructive sales grew only 1.5% on a reported basis in Q4. How much of this is lingering drag from the Arvis delays discussed earlier in the year, versus fundamental market share loss or pricing pressure?